BDSX vs PATH · rev $71.3M vs P/E 19, rev $1.61B
Biodesix Inc (BDSX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Biodesix Inc (BDSX) is a diagnostics & research company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported BDSX revenue for 2024-12-31 was $71.3M. Net income was -$42.9M. Revenue was up 45.3% from 2023-12-31 to 2024-12-31. BDSX currently screens at market cap $157.6M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
BDSX currently screens at market cap $157.6M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the BDSX and PATH stock pages for the full models.
Not investment advice.